The JUN Knockout DLD-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the DLD-1 human colorectal adenocarcinoma cell line, providing targeted disruption of the JUN gene that encodes the c-Jun transcription factor. This polyclonal pool, generated through CRISPR/Cas9-mediated gene disruption, contains a heterogeneous mixture of cells with diverse loss-of-function alleles at the JUN locus, enabling robust loss-of-function studies without clonal selection.
The parental DLD-1 cell line was established from a primary colorectal adenocarcinoma of a male patient and is a widely utilized cellular model for colorectal carcinoma. These cells harbor oncogenic mutations typical of colorectal cancer, including in APC and KRAS, and are extensively employed to investigate tumor cell proliferation, survival signaling, invasion, and drug responses, providing a clinically relevant background for examining gene function in colon cancer.
JUN encodes c-Jun, a central component of the AP-1 transcription factor complex that governs gene expression programs in response to diverse stimuli. c-Jun is primarily activated by JNK (MAPK8/9)-mediated phosphorylation, which occurs downstream of receptor tyrosine kinases stimulated by growth factors such as EGF and PDGF, as well as pro-inflammatory cytokines like TNF and IL-1. The Ras-Raf-MEK-ERK cascade also converges on c-Jun activation. Upon phosphorylation, c-Jun heterodimerizes with FOS family members (c-Fos, FosB, Fra-1, Fra-2) or partners such as ATF2 and CREB to bind AP-1 elements in target gene promoters. This complex transcriptionally regulates key effectors including Cyclin D1 for cell cycle progression, MMP9 and VEGF for matrix remodeling and angiogenesis, and Bcl-2 and FasL for apoptosis modulation. Additionally, c-Jun functionally interacts with NF-??B and ??-catenin, integrating multiple signaling inputs to finely tune cell fate decisions.
In DLD-1 colorectal adenocarcinoma cells, CRISPR/Cas9-mediated disruption of JUN expression cripples the AP-1 transcriptional machinery that transduces oncogenic and stress signals often hyperactive in colorectal cancer. Loss of c-Jun abrogates the induction of pro-proliferative and pro-invasive genes such as Cyclin D1 and MMP9, leading to impaired cell growth, enhanced apoptosis, and diminished invasive capacity. As such, this knockout model provides a unique platform to dissect the dependency of colorectal cancer cells on JNK/c-Jun/AP-1 signaling and to explore the mechanistic basis of the transformed phenotype.
The JUN Knockout DLD-1 Polyclonal Cells are suited for a broad spectrum of functional assays. Standard approaches include western blotting and RT-qPCR to confirm c-Jun depletion and monitor downstream target expression, MTT or BrdU proliferation assays, caspase activity assays for apoptosis, and Transwell invasion assays to assess metastatic potential. Luciferase-based AP-1 reporter assays and ChIP-qPCR enable direct measurement of transcriptional activity and promoter occupancy, while RNA-seq permits transcriptome-wide mapping of c-Jun-dependent gene networks. Additional applications encompass colony formation assays and drug sensitivity profiling for screening JNK/AP-1 pathway inhibitors. For further information, please contact Ascent Research.
